Evaluation of the Antiviral Response to Zanamivir Administered Intravenously for Treatment of Critically Ill Patients With Pandemic Influenza A (H1N1) Infection
نویسندگان
چکیده
A retrospective nationwide study on the use of intravenous (IV) zanamivir in patients receiving intensive care who were pretreated with oseltamivir in the Netherlands was performed. In 6 of 13 patients with a sustained reduction of the viral load, the median time to start IV zanamivir was 9 days (range, 4-11 days) compared with 14 days (range, 6-21 days) in 7 patients without viral load reduction (P = .052). Viral load response did not influence mortality. We conclude that IV zanamivir as late add-on therapy has limited effectiveness. The effect of an immediate start with IV zanamivir monotherapy or in combination with other drugs need to be evaluated.
منابع مشابه
Intravenous zanamivir in critically ill patients due to pandemic 2009 (H1N1) influenza A virus.
INTRODUCTION The 2009 (H1N1) influenza A pandemic started in April 2009 and has since spread globally. We have noticed that critically ill patients with confirmed pandemic 2009 (H1N1) influenza A require mechanical ventilation. This paper describes the use of intravenous zanamivir in this group of patients. METHODS Patients who had severe pneumonia with 2009 (H1N1) influenza A and required in...
متن کاملInfluenza: The 2009 H1N1 Pandemic And Antiviral Treatment Options
Purpose. To provide an overview of the 2009 H1N1 influenza pandemic and antiviral treatment options for influenza. Summary. Influenza infection causes significant morbidity and mortality every year. The high mutation rate and segmented nature of influenza virus genome gives rise to high genetic variability which enables the virus to escape antiviral and vaccine interventions. A novel H1N1 strai...
متن کاملUse of intravenous zanamivir after development of oseltamivir resistance in a critically Ill immunosuppressed child infected with 2009 pandemic influenza A (H1N1) virus.
Immunosuppressed patients receiving oseltamivir for 2009 novel H1N1 influenza A infection may develop drug resistance, leading to treatment failure. Intravenous zanamivir was administered on a compassionate-use basis to a profoundly immunosuppressed pediatric patient with severe oseltamivir-resistant novel H1N1 pneumonia. The regimen was well tolerated and was associated with a decrease in vira...
متن کاملTreatment of Immunocompromised, Critically Ill Patients with Influenza A H1N1 Infection with a Combination of Oseltamivir, Amantadine, and Zanamivir
Immunocompromised patients are at increased risk of complications of influenza virus infection. We report on two critically ill patients on immunosuppressive medication with influenza pneumonia. In both patients, oseltamivir monotherapy did not result in clearance of the virus after 18 and five days, respectively. After adding zanamivir and amantadine to the treatment, PCRs on pharyngeal and/or...
متن کاملClinical experience with intravenous zanamivir under an emergency investigational new drug program in the United States.
TO THE EDITOR—We read the article by Fraaij et al [1] and would like to summarize the available information on intravenous zanamivir from the Food and Drug Administration (FDA)'s Emergency Investigational New Drug (EIND) application process [2]. No intravenous an-tiviral agents for treatment of severe influenza are currently approved in the United States. Since the emergence of 2009 pandemic in...
متن کامل